Nephros, Inc. (NEPH)

NASDAQ: NEPH · USD

$3.20

-0.04 (-1.2%)· Recorded snapshot

Market cap	34.8M
Revenue (ttm)	20.7M
Net income (ttm)	1.7M
EPS (ttm)	$0.16
Shares out	10.9M
P/E (trailing)	20.0x
P/E (forward)	16.8x
Volume	5,337
Beta	1.75

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 20.7M
Net income (ttm): 1.7M
EPS (ttm): $0.16
P/E (trailing): 20.0x
P/E (forward): 16.8x
Market cap: 34.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 20:55 UTC

Forward P/E16.8

P25 n/aP50 n/aP75 n/a

Trailing P/E20

P25 n/aP50 n/aP75 n/a

ROE16.1

P25 n/aP50 n/aP75 n/a

ROIC20.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NEPH indicators

Market & fundamental data

Available fields

244

Groups with data

Currency

USD

Showing 244 of 244 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001196298
Company name	Nephros, Inc.
Country	United States
Country code	US
CUSIP number	640671400
Earnings date	2026-11-05
Earnings time	amc
Employees	36
Employees change	5
Employees growth	16.13%
Enterprise value	$30.9M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1997
Industry	Medical Instruments & Supplies
IPO date	2004-09-21
Is primary listing	Yes
Is SPAC	No
ISIN number	US6406714005
Last 10-K release date	2026-03-12
Last earnings date	2026-08-06
Last refreshed	2026-11-04
Last stock split date	2019-07-10
Last stock split type	Reverse
Market cap	$34.8M
Market cap category	Nano-Cap
Next earnings date	2026-11-05
Options	No
Price	$3.20
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-11-04
Symbol	NEPH
U.S. state	New Jersey
Website	https://www.nephros.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	30.68x
Earnings yield	5%
EV/Earnings	18.24x
EV/EBIT	19.28x
EV/EBITDA	17.91x
EV/Sales	1.53x
FCF / EV yield	-2.09%
FCF yield	-1.86%
Forward EV/Sales	1.33x
Forward P/E	16.84x
Forward P/S	1.49x
Graham number	1.99199
Graham upside	-39.04%
Industry forward P/E	22.48x
Industry P/E	61.2x
P/B ratio	2.94x
P/E ratio	20x
P/S ratio	1.71x
Price / tangible book value	3.3x
Price/EBITDA ratio	20.07x
Sector forward P/E	24x
Sector P/E	49.18x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	7.92%
EBITDA margin	8.53%
Effective tax rate	0.91%
Gross margin	61.26%
Operating margin	7.92%
Pretax margin	8.45%
Profit margin	8.38%
Profit per employee	$48,222
Profitable quarters	8
Profitable years	2
Revenue per employee	$575,611
ROA	7.33%
ROA (5Y)	-6.61%
ROCE	13.21%
ROE	16.1%
ROE (5Y)	-11.85%
ROIC	20.6%
ROIC (5Y)	-20.03%
SBC / revenue	1.3%
Tax / revenue	0.08%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	34.27%
EPS growth (Q)	450%
EPS growth (QoQ)	1,000.11%
EPS growth quarters	1
EPS growth years	3
FCF growth (Q)	-31.49%
Gross profit growth	20.07%
Gross profit growth (Q)	44.04%
Gross profit growth 3Y	25.17%
Gross profit growth 5Y	18.69%
Net income growth	30.82%
Net income growth (Q)	405.06%
Net income growth (QoQ)	755%
Net income growth quarters	1
Net income growth years	3
OCF growth (Q)	-31.49%
Operating income growth	22.81%
Operating income growth (Q)	389.11%
Revenue growth	24.2%
Revenue growth (Q)	36.16%
Revenue growth (QoQ)	15.45%
Revenue growth 10Y	26.78%
Revenue growth 3Y	19.29%
Revenue growth 5Y	16.99%
Revenue growth quarters	7
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$126,000
EBIT	$1.6M
EBITDA	$1.8M
EPS	$0.16
FCF per share	$-0.06
Financing cash flow	$284,000
Free cash flow	$-661,000
Free cash flow minus SBC	$-931,000
Gross profit	$12.7M
Income taxes	$16,000
Net borrowing	$-6,000
Net cash flow	$-377,000
Net income	$1.7M
Operating cash flow minus SBC	$-931,000
Operating income	$1.6M
Revenue	$20.7M
Stock-based compensation	$270,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.3
Book value per share	$1.10
Debt / EBITDA	0.39
Debt / equity	0.07
Goodwill	$759,000
Interest coverage	1,642
Long-term assets	$2.2M
Long-term liabilities	$458,000
Net cash (debt)	$3.8M
Net cash / market cap	10.78%
Net cash growth	-0.21%
Net debt / EBITDA	-2.16
Net debt / equity	-0.32
Piotroski F-Score	3
Property, plant and equipment	$915,000
Shareholders' equity	$12M
Tangible book value	$10.8M
Tangible book value per share	$0.99
Total assets	$15.8M
Total cash	$4.7M
Total debt	$872,000
Total liabilities	$3.8M
WACC	13.57%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.48
Current assets	$13.6M
Current liabilities	$3.3M
Current ratio	4.07
Inventory turnover	2.37
Net working capital	$6M
Quick ratio	2.63
Working capital	$10.3M
Working capital turnover	2.3

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-4.21%
Dividend yield	0%
Shareholder yield	-4.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	22.48%
10Y return CAGR	2.05%
10Y total return	22.51%
150-day SMA	$3.60
15Y price change	-64.87%
15Y return CAGR	-6.74%
15Y total return	-64.87%
1D price change	-1.23%
1M price change	-12.13%
1M total return	-12.13%
1W price change	1.74%
1W total return	1.74%
1Y price change	-39.94%
1Y return CAGR	-39.97%
1Y total return	-39.94%
20-day SMA	$3.45
200-day SMA	$3.65
20Y price change	-98.47%
20Y return CAGR	-18.86%
20Y total return	-98.47%
3M price change	-8.12%
3M total return	-8.12%
3Y price change	97.85%
3Y return CAGR	25.53%
3Y total return	97.85%
50-day SMA	$3.84
50-day SMA vs 200-day SMA	50over200
52-week high	$6.42
52-week high date	2025-11-26
52-week low	$2.66
52-week low date	2026-04-07
5Y price change	-58.58%
5Y return CAGR	-16.16%
5Y total return	-58.58%
6M price change	3.7%
6M total return	3.7%
All-time high	$1,128.60
All-time high date	2004-09-28
All-time low	$0.90
All-time low date	2011-03-23
Average true range (ATR)	$0.25
Average volume	51.3K
Beta (1Y)	1.48
Beta (2Y)	-0.2
Beta (5Y)	1.75
Change from 52-week high	-50.16%
Change from 52-week low	20.17%
Change from all-time high	-99.71%
Change from all-time low	258.33%
Change from open	-2.44%
Day's gap	1.23%
Dollar volume	$17,078
High price	$3.30
Low price	$3.20
Monthly RSI	48.63
Open price	$3.28
Position in 52-week range	0%
Previous close	$3.24
Price vs 150-day SMA	-10.44%
Price vs 20-day SMA	-6.47%
Price vs 200-day SMA	-11.57%
Price vs 50-day SMA	-16.06%
Relative volume	0.1
RSI	38.95
Sharpe ratio	-0.23
Sharpe ratio (3Y)	0.61
Sharpe ratio (5Y)	0.1
Sortino ratio	-0.28
Sortino ratio (3Y)	1.14
Sortino ratio (5Y)	0.24
Volume	5.3K
Weekly RSI	42.3
YTD price change	-33.91%
YTD total return	-33.91%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8.9M
Float percentage	82.22%
Shares change (QoQ)	1.11%
Shares change (YoY)	4.21%
Shares held by insiders	17.78%
Shares held by institutions	17.87%
Shares outstanding	10.9M
Short % of float	0.17%
Short % of shares	0.14%
Short ratio	0.4 days

Deeper analysis on NEPH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NEPH report

Is a complete NEPH research report available?

No complete published report is available for Nephros, Inc. (NEPH) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Nephros, Inc. (NEPH)

Price

Financial snapshot

Fair-value bridge

Latest news · NEPH

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NEPH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NEPH

Frequently asked questions